Companies › Genetix Biotherapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Hematology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lovotibeglogene Autotemcel (bb1111) Hemoglobin beta chain exogenous gene | HBB | Phase 3 | Sickle Cell Disease | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04293185 | Lovotibeglogene Autotemcel (bb1111) | Phase 3 | Sickle Cell Disease | Hematology | May 2027 |
Shanghai Xinzhi BioMed Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Grand Shuyang Life Sciences (Chengdu) Gritgen Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.